v3.26.1
Revenues
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Revenues are recognized under guidance within ASC 606, Revenue from Contracts with Customers. The following table presents the Company's disaggregated revenue for the periods presented (in thousands):
Three Months Ended June 30,
Six Months Ended June 30,
2026202520262025
ZORYVE cream 0.3%
$35,327 $27,675 $67,997 $51,062 
ZORYVE foam
67,377 39,212 117,004 69,452 
ZORYVE cream 0.15%24,231 14,617 45,972 24,836 
ZORYVE cream 0.05%2,926 — 4,286 — 
Total product revenue, net
129,861 81,504 235,259 145,350 
Other revenue
— — — 2,000 
Total revenues
$129,861 $81,504 $235,259 $147,350 
Other revenue for the six months ended June 30, 2025 relates to the licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong). See Note 6.
Product revenue, net, from customers located outside the United States represented less than 10% of the Company’s consolidated product revenue, net, for all periods presented.